Serious but rare risks include pancreatitis, gallbladder disease, acute kidney injury secondary to dehydration, and hypersensitivity reactions
According to the Summary of Product Characteristics (SmPC), these include: Nausea (very common) Vomiting (common) Diarrhoea (very common) Constipation (common) Abdominal pain or discomfort (common) Decreased appetite (very common) These symptoms typically diminish over time as the body adjusts to the medication
That's your tirzepatide, produced by Eli Lilly
Published preclinical and clinical research has examined retatrutide in the context of
Although Pac1r / mice exhibit a complex metabolic phenotype, they display significant glucose intolerance and defective insulin secretion after both oral and iv glucose and impaired insulinotropic responses to PACAP, but not VIP, consistent with the importance of endogenous PACAP for control of insulin secretion (115)
This product should not be used as a substitute for a balanced and varied diet
